| Metric | Value ($ M) |
|---|---|
| Revenue | 1.90 |
| Total Income | 1.90 |
| Expenditure | 46.04 |
| PBT | — |
| Net Profit | -41.49 |
| OPM | — |
| NPM | — |
| EPS | -1.32 |
LENZ Therapeutics Reports Q1 2026 Total Revenue of $1.9 Million
12 May 2026 · 12 May, 1:45 am
Summary
LENZ Therapeutics reported total revenue of $1.9 million for the first quarter of 2026, with product sales of VIZZ reaching $1.7 million, marking a 19% increase over the previous quarter. The company experienced a substantial net loss of $41.5 million, primarily driven by significant investments in selling, general, and administrative expenses to support the commercial launch of VIZZ. Management expressed confidence in the long-term opportunity for VIZZ, citing strong early refill dynamics and progress in building consumer awareness and engagement through direct-to-consumer campaigns.
Key Highlights
- 1
LENZ Therapeutics reported total revenue of $1.9 million for the first quarter of 2026, which included $1.7 million in VIZZ product sales.
- 2
Product sales for Q1 2026 increased by 19% to $1.7 million compared to Q4 2025, driven by approximately 25,000 paid prescriptions of VIZZ.
- 3
From launch through Q1 2026, approximately 46,000 paid prescriptions of VIZZ were filled, with over 10,000 unique eye care professionals prescribing the product.
- 4
Selling, General and Administrative (SG&A) expenses significantly increased to $45.0 million in Q1 2026, up from $11.1 million in the same period of 2025, primarily due to planned launch investments.
- 5
The company reported a net loss of $41.5 million, or $1.32 per share, for the three months ended March 31, 2026, compared to a net loss of $14.6 million, or $0.53 per share, in Q1 2025.
- 6
Research and Development (R&D) expenses decreased to zero in Q1 2026 from $5.8 million in Q1 2025, following the FDA approval of VIZZ in July 2025.
- 7
Cash, cash equivalents, and marketable securities stood at $258.4 million as of March 31, 2026, which is anticipated to fund operations to post-launch positive cash flow.
Management Comments
Eef Schimmelpennink
We have made significant progress in the early quarters of launch driving high ECP awareness, growing prescriber experience and confidence with VIZZ, and have started to build consumer awareness and engagement through our DTC campaigns as we establish a new market for the treatment of presbyopia. VIZZ is delivering the kind of real-world efficacy we believed it could, and the early refill dynamics we are seeing continue to reinforce our confidence in the long-term opportunity. Looking ahead, we are focused on helping ECPs integrate VIZZ seamlessly into their practices, improving the patient path from awareness to activation, and continuing to drive adoption as we build this exciting treatment category.
Informational and educational content only. Not investment advice.